Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Philip Jarvis"'
Autor:
Heinfried H. Radeke, Jürgen Stein, Gert Van Assche, Gerhard Rogler, Peter L. Lakatos, Florian Muellershausen, Pierre Moulin, Philip Jarvis, Laurence Colin, Peter Gergely, Wolfgang Kruis
Publikováno v:
Inflammatory Intestinal Diseases, Pp 1-11 (2020)
Background and Aims: KRP203 is a potent oral agonist of the sphingosine-1-phosphate receptor subtype 1 that induces the sequestration of peripheral lymphocytes, thereby potentially reducing the number of activated lymphocytes circulating to the gastr
Externí odkaz:
https://doaj.org/article/b2995644ed9f4c96bffe9657f67e3707
Autor:
Alexa B. Kimball, Christian Loesche, Errol P. Prens, Falk G. Bechara, Jamie Weisman, Izabela Rozenberg, Philip Jarvis, Thomas Peters, Lukas Roth, Grazyna Wieczorek, Frank Kolbinger, Gregor B. E. Jemec
Publikováno v:
Experimental Dermatology, 31(10), 1522-1532. Wiley-Blackwell Publishing Ltd
Kimball, A B, Loesche, C, Prens, E P, Bechara, F G, Weisman, J, Rozenberg, I, Jarvis, P, Peters, T, Roth, L, Wieczorek, G, Kolbinger, F & Jemec, G B E 2022, ' IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa : Combined results from a pre-clinical and phase II proof-of-concept study ', Experimental Dermatology, vol. 31, no. 10, pp. 1522-1532 . https://doi.org/10.1111/exd.14619
Kimball, A B, Loesche, C, Prens, E P, Bechara, F G, Weisman, J, Rozenberg, I, Jarvis, P, Peters, T, Roth, L, Wieczorek, G, Kolbinger, F & Jemec, G B E 2022, ' IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa : Combined results from a pre-clinical and phase II proof-of-concept study ', Experimental Dermatology, vol. 31, no. 10, pp. 1522-1532 . https://doi.org/10.1111/exd.14619
Hidradenitis Suppurativa (HS) is a chronic, recurrent, inflammatory, follicular skin disease whose pathology is complex and not fully understood. The objective of this study was to elucidate the role of IL-17A in moderate-to-severe HS. Transcriptomic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe4c1906ff2cb356fdb9a1da421347ab
https://pure.eur.nl/en/publications/1de72b10-68ef-421c-89e8-672626f23dcc
https://pure.eur.nl/en/publications/1de72b10-68ef-421c-89e8-672626f23dcc
Autor:
Anthony George, Philip Jarvis
Publikováno v:
Clinical Radiology. 77:e25-e26
Publikováno v:
Archives of disease in childhood. Education and practice edition. 107(4)
Case presentationA 14-year-old boy, with autism spectrum disorder, presented with a 1-day history of colicky abdominal pain, non-bilious vomiting, anorexia and loose normal-coloured stool. Two days previously, he had a poorly reheated takeaway chicke
Autor:
J M Rondeau, R Mussmann, R Cebe, Philip Jarvis, Thomas Huber, I Rozenberg, Claudio Calonder, Maher Aassi, Frank Kolbinger, T S Sligh, M Kaul, P Espie, F Di Padova
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Background and objective Anti‐IL‐17A IgG/κ monoclonal antibody CJM112 binds both IL‐17A and IL‐17AF. The purpose of this First‐in‐Human study was to assess CJM112 effects on safety and efficacy in patients with moderate to severe plaque
Autor:
Peter Gergely, Laurence Colin, Peter L. Lakatos, Heinfried H. Radeke, Jürgen Stein, Pierre Moulin, Gert Van Assche, Gerhard Rogler, Philip Jarvis, Florian Muellershausen, Wolfgang Kruis
Publikováno v:
Inflammatory Intestinal Diseases, Pp 1-11 (2020)
Inflamm Intest Dis
Inflamm Intest Dis
Background and Aims: KRP203 is a potent oral agonist of the sphingosine-1-phosphate receptor subtype 1 that induces the sequestration of peripheral lymphocytes, thereby potentially reducing the number of activated lymphocytes circulating to the gastr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b2ace75c357720483ecd0948419b9c7
https://www.karger.com/Article/FullText/509393
https://www.karger.com/Article/FullText/509393
Autor:
Maxime Tenon, Frank Kolbinger, Bernard Maillere, Philip Jarvis, Anette Karle, Evelyne Correia, Sebastian Spindeldreher
Publikováno v:
Dermatology and Therapy
Introduction Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy in the treatment of moderate to severe plaque psoriasis (PsO) and psoriatic arthritis (PsA), demonstrating a
Autor:
Andy N. Mead, Pierre Jordaan, Kathryn Chapman, Will S. Redfern, Alessandra Giarola, Jean-Pierre Valentin, Samuel J. Jackson, Lorna Ewart, Philip Jarvis, Hugo M. Vargas, Martin Traebert, Hamid R. Amouzadeh
Publikováno v:
Regulatory Toxicology and Pharmacology. 80:348-357
Central Nervous System (CNS)-related safety concerns are major contributors to delays and failure during the development of new candidate drugs (CDs). CNS-related safety data on 141 small molecule CDs from five pharmaceutical companies were analyzed
Autor:
Janice Canvin, Rainer Hillenbrand, Panayiotis Georgiou, Petra Staubach, Michael Kangas, Marcus Maurer, Philip Jarvis, Randolf Brehler, Martin Metz, Janine Gericke, Joanna Ashton-Chess, Andrea Bauer, Veit J. Erpenbeck
Publikováno v:
Theranostics
Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has not been elucidated in de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55f7f449b5f1f4cec3e25ea505253cb6
https://refubium.fu-berlin.de/handle/fub188/20880
https://refubium.fu-berlin.de/handle/fub188/20880